147076-36-6
147076-36-6 結(jié)構(gòu)式
基本信息
LCBOKWGFIPORJD-QBFSEMIESA-N
2-Propenamide, 2-cyano-3-cyclopropyl-3-hydroxy-N-[3-methyl-4-(trifluoromethyl)phenyl]-, (2Z)-
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-101813R | 拉氟莫司 Laflunimus (Standard) | 147076-36-6 | 1 mg | 2400元 |
| 2026/06/05 | HY-101813R | 拉氟莫司 Laflunimus (Standard) | 147076-36-6 | 5 mg | 6000元 |
| 2026/06/05 | HY-101813 | 拉氟莫司 Laflunimus | 147076-36-6 | 1 mg | 1363元 |
常見問題列表
Ig secretion from mouse splenocytes was induced by lipopolysaccharide (LPS) for 5 days. Laflunimus inhibited the secretion of IgM and IgG with IC
50
values of 2.5 and 2 μM , respectively. Adding Uridine (50 μ M) increased these values to 70 and 60 μ M, respectively. Laflunimus inhibits LPS-induced kappa light-chain cell surface expression on 70Z/3 cells, a property also reversed by uridine.
Laflunimus (HR325) is more potent than A77 1726 as an inhibitor of PGHS in guinea pig polymorphonuclear leukocytes (IC
50
= 415 and 4400 nM, respectively) and on isolated ovine PGHS-1 (IC
50
=64 and 742 μM) and PGHS-2 (IC
50
=100 and 2766 μM).
HR325 (50 mg/kg; p.o.; days 14-18 after being injected with SRBC) inhibits the secondary anti-sheep red blood cell (SRBC) antibody response with ID 50 values of 38 mg/kg.
| Animal Model: | Male CD-1 mice (20-24 g) |
| Dosage: | 50 mg/kg |
| Administration: | Oral; days 14-18 after being injected with SRBC |
| Result: | The level of circulating anti-SRBC IgG in this model was inhibited dose relatedly by orally administered HR325. |